Remidio Innovative Solutions Pvt. Ltd., a frontrunner in ophthalmic technology, has received regulatory approval from the State FDA, Karnataka (CDSCO) for its Medios HI Glaucoma AI and Medios HI AMD AI. These new approvals mark a significant milestone in harnessing artificial intelligence for early detection of glaucoma and age-related macular degeneration (AMD) across varied healthcare environments.
Building on the Success of Medios HI DR AI
These advancements follow the success of Remidio’s Medios DR HI—an AI tool for diabetic retinopathy—which received CDSCO approval earlier and has screened nearly 2,50,000 patients in the past year. Like its predecessor, the newly approved AI tools for glaucoma and AMD operate offline, allowing instant image analysis without internet dependency. This feature is particularly impactful in remote and underserved areas where access to specialist diagnostics is limited.
Transforming Glaucoma Detection with AI
As per the press release, the Medios HI Glaucoma AI enhances traditional screening methods by analyzing the optic nerve head and retinal nerve fiber layer (RNFL) structures. It produces heat map–based reports to flag early signs of referable glaucoma. In India, where 12 million people suffer from glaucoma—almost one in eight globally—over 90% remain undiagnosed. This tool offers a transformative solution, enabling early detection that can prevent irreversible vision loss.
Early Detection of AMD Made Accessible
Medios HI AMD AI identifies early-stage AMD, a leading cause of visual impairment among the elderly. In India, 2.1% of individuals over 60—about 6.7 million people—are at risk. This AI system uses heat maps to pinpoint retinal lesions. It enables timely referral and preventive care, particularly in primary and community healthcare settings.
Clinically Validated, Seamlessly Integrated
Remidio’s AI tools have undergone extensive clinical validation at tertiary hospitals, leading eye institutes, and vision centers. Both AI models demonstrated high sensitivity and specificity, aligning closely with expert diagnoses. When used with Remidio’s FOP NM 10 fundus camera, the Medios HI platform provides screening for AMD, glaucoma, and diabetic retinopathy. All of this can be done with a single tap and within seconds.
Expert Endorsements Highlight Impact
Dr. R. Kim, Chief Medical Officer at Aravind Eye Hospital, Madurai, praised the innovation, stating, “The Remidio fundus camera isn’t just an imaging device; it’s a portable gateway to early detection and prevention of vision-threatening conditions, bringing quality eye care closer to those who need it most.”
Dr. Anand Sivaraman, CEO and Founding Director of Remidio, emphasized the broader vision: “The CDSCO’s approval of our glaucoma and AMD AI builds on our pioneering DR AI. These tools are helping us reach underserved populations, offering early diagnosis and meaningful intervention.”
Dr. Divya Rao, Chief Medical Officer at Remidio, added, “These approvals validate the clinical precision of our AI. What excites us most is that these tools enable specialist-grade diagnostics at the primary care level.”
Sundeep Agarwal, Senior VP – Regulatory Affairs & Quality Assurance, remarked, “Achieving CDSCO approval is a significant milestone. It reflects our unwavering commitment to regulatory excellence, patient safety, and scalable, compliant innovation.”
Driving Scalable, Equitable Eye Care
Remidio integrates its AI tools with portable fundus imaging devices to ensure seamless deployment across clinical environments. The offline functionality plays a critical role in extending eye care to rural and low-resource settings, eliminating reliance on internet connectivity.
Leading the Future of AI-Powered Ophthalmology
With these latest approvals, Remidio continues to lead the charge in AI-driven ophthalmic diagnostics. The company remains focused on closing the gap in eye care delivery. It aims to reduce vision impairment through timely, accessible, and intelligent screening solutions.